Supplementary Material for: Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

<b><i>Background:</i></b> Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. <b><i>Objective:</i></b> To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. <b><i>Methods:</i></b> This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. <b><i>Results:</i></b> Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). <b><i>Study Limitations:</i></b> The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. <b><i>Conclusion:</i></b> Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients.